Advanz Pharma

Advanz Pharma is a global pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, Canada and Australia, committed to improving the lives of patients by providing and enhancing the medicines they depend on.

Company Background

• Agile and experienced team, including direct sales, marketing and medical capability across Europe’s major markets, and a global distribution network.
• Commercial sales in more than 90 countries globally and direct presence in over 20 countries, including key countries in Europe, the US, Canada and Australia.
• Comprehensive product portfolio that includes innovative medicines, specialty generics & biosimilars, and originator brands.
• Broad expertise in several therapeutic areas with particular strengths in critical care, anti-infectives, endocrinology, cardiovascular, CNS and more broadly on rare disease medicines, particularly in hepatology and gastroenterology.

Vision & Outlook

• Further grow its position as a partner of choice for specialty and hospital pharmaceuticals in Europe and beyond.
• Invest in a strengthened platform – to accelerate the company’s pipeline of innovative specialty pharmaceutical products.

Highlights & Updates

• Strategic acquisitions include Intercept Pharmaceutical's subsidiaries and operations in Europe, Canada and other markets outside of the US, completed 2022, and Androcur, an anti-androgen therapy, in 2023.
• Combination more than doubles Advanz Pharma's commercial and medical team with sizeable additions across major EU countries.
• Extended its strategic partnership with Alvotech, to commercialise five proposed biosimilars in Europe, in 2023. Will leverage the company's existing specialty and hospital capabilities in Europe to ensure successful market registration, commercialisation, and patient access.